CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia - Effects of 7 reference compounds at 10 facilities

Journal of Pharmacological and Toxicological Methods

Volumn 78, Issue , 2016, Pages 93-102

  Kitaguchi, Takashi ^a,b,c   Moriyama, Yuta ^b,c   Taniguchi, Tomohiko ^b,d   Ojima, Atsuko ^b,d   Ando, Hiroyuki ^b,e   Uda, Takaaki ^b,e   Otabe, Koji ^b,f   Oguchi, Masao ^b,f   Shimizu, Shigekazu ^b,g   Saito, Hiroyuki ^b,g   Morita, Maya ^b,h   Toratani, Atsushi ^b,i   Asayama, Mahoko ^b,i   Yamamoto, Wataru ^b,j   Matsumoto, Emi ^b,j   Saji, Daisuke ^b,k   Ohnaka, Hiroki ^b,k   Tanaka, Kohji ^b,l   Washio, Ikumi ^b,l   Miyamoto, Norimasa ^a,b,d  

^a Drug Evaluation Committee   (Japan)

^b Consortium for Safety Assessment using Human iPS Cells ^*  (Japan)

^c MOCHIDA PHARMACEUTICAL CO   (Japan)

^d EISAI CO LTD   (Japan)

^e ONO PHARMACEUTICAL CO   (Japan)

^f N   (Japan)

^g Bioresearch Center   (Japan)

^h TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

ⁱ MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^j TEIJIN PHARMA LIMITED   (Japan)

^k Research Department   (Japan)

^l NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

more..

Author keywords

CSAHi; Field potential; Human induced pluripotent stem cell derived cardiomyocytes; Multi electrode array; Proarrhythmia; QT prolongation; Torsade de pointes

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ACETYLSALICYLIC ACID; CHROMANOL 293B; FLECAINIDE; MOXIFLOXACIN; TERFENADINE; VERAPAMIL; DRUG;

ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; BEAT RATE; CARDIOVASCULAR PARAMETERS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; FIELD POTENTIAL DURATION; HEART ARRHYTHMIA; HEART MUSCLE CELL; HUMAN; HUMAN CELL; INCIDENCE; MULTIELECTRODE ARRAY; NONHUMAN; PLURIPOTENT STEM CELL; QT PROLONGATION; REPRODUCIBILITY; TORSADE DES POINTES; WAVEFORM; ARRHYTHMIAS, CARDIAC; CARDIAC MUSCLE CELL; CELL CULTURE TECHNIQUE; CHEMICALLY INDUCED; CLINICAL TRIAL; CRYOPRESERVATION; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVALUATION STUDY; INDUCED PLURIPOTENT STEM CELL; LONG QT SYNDROME; MULTICENTER STUDY; ORGANIZATION; PHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES;

ARRHYTHMIAS, CARDIAC; CELL CULTURE TECHNIQUES; CONGRESSES AS TOPIC; CRYOPRESERVATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LONG QT SYNDROME; MYOCYTES, CARDIAC; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS;

EID: 84949843626     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2015.12.002     Document Type: Article

References (32)

1. Asakura K., Hayashi S., Ojima A., Taniguchi T., Miyamoto N., Nakamori C., Sawada K. Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes. Journal of Pharmacological and Toxicological Methods 2015, 75:17-26.
2. Carlsson L. In vitro and in vivo models for testing arrhythmogenesis in drugs. Journal of Internal Medicine 2006, 259(1):70-80.
3. Cavero I., Holzgrefe H. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: A visionary 21st century initiative. Expert Opinion on Drug Safety 2014, 13(6):745-758.
4. Chaves A.A., Zingaro G.J., Yordy M.A., Bustard K.A., O'Sullivan S., Galijatovic-Idrizbegovic A., Briscoe R.J. A highly sensitive canine telemetry model for detection of QT interval prolongation: Studies with moxifloxacin, haloperidol and MK-499. Journal of Pharmacological and Toxicological Methods 2007, 56(2):103-114.
5. Clements M., Thomas N. High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. Toxicological Sciences 2014, 140(2):445-461.
6. Gibson J.K., Yue Y., Bronson J., Palmer C., Numann R. Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents. Journal of Pharmacological and Toxicological Methods 2014, 70(3):255-267.
7. Harris K., Aylott M., Cui Y., Louttit J.B., McMahon N.C., Sridhar A. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicological Sciences 2013, 134(2):412-426.
8. Hayakawa T., Kunihiro T., Ando T., Kobayashi S., Matsui E., Yada H., Furukawa T. Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology. Journal of Molecular and Cellular Cardiology 2014, 77:178-191.
9. Heijman J., Voigt N., Carlsson L.G., Dobrev D. Cardiac safety assays. Current Opinion in Pharmacology 2014, 15:16-21.
10. ICH S7B: The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Tech. Rep. 2005, (URL http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf).
11. ICH E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Tech. Rep. 2005, (URL http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf).
12. Kaneko T., Nomura F., Hamada T., Abe Y., Takamori H., Sakakura T., Yasuda K. On-chip in vitro cell-network pre-clinical cardiac toxicity using spatiotemporal human cardiomyocyte measurement on a chip. Scientific Reports 2014, 4:4670.
13. Kannankeril P., Roden D.M., Darbar D. Drug-induced long QT syndrome. Pharmacology Reviews 2010, 62(4):760-781.
14. Kramer J., Obejero-Paz C.A., Myatt G., Kuryshev Y.A., Bruening-Wright A., Verducci J.S., Brown A.M. MICE models: Superior to the HERG model in predicting Torsade de Pointes. Scientific Reports 2013, 3:2100.
15. Kraushaar U., Meyer T., Hess D., Gepstein L., Mummery C.L., Braam S.R., Guenther E. Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models. Expert Opinion on Drug Safety 2012, 11(2):285-298.
16. Liu T., Traebert M., Ju H., Suter W., Guo D., Hoffmann P., Yan G.X. Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: A blinded validation. Heart Rhythm 2012, 9(10):1706-1715.
17. Monahan B.P., Ferguson C.L., Killeavy E.S., Lloyd B.K., Troy J., Cantilena L.R. Torsades de pointes occurring in association with terfenadine use. The Journal of the American Medical Association 1990, 264(21):2788-2790.
18. Morissette P., Nishida M., Trepakova E., Imredy J., Lagrutta A., Chaves A., Salata J.J. The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model. Journal of Pharmacological and Toxicological Methods 2013, 68(1):137-149.
19. Nakamura Y., Matsuo J., Miyamoto N., Ojima A., Ando K., Kanda Y., Sekino Y. Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell-derived cardiomyocyte sheet: Multi-site validation study. Journal of Pharmacological Sciences 2014, 124(4):494-501.
20. Omata T., Kasai C., Hashimoto M., Hombo T., Yamamoto K. QT PRODACT: Comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. Journal of Pharmacological Sciences 2005, 99(5):531-541.
21. Peng S., Lacerda A.E., Kirsch G.E., Brown A.M., Bruening-Wright A. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. Journal of Pharmacological and Toxicological Methods 2010, 61(3):277-286.
22. Peters M.F., Lamore S.D., Guo L., Scott C.W., Kolaja K.L. Human stem cell-derived cardiomyocytes in cellular impedance assays: Bringing cardiotoxicity screening to the front line. Cardiovascular Toxicology 2015, 15(2):127-139.
23. Pollard C.E., Abi Gerges N., Bridgland-Taylor M.H., Easter A., Hammond T.G., Valentin J.P. An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. British Journal of Pharmacology 2010, 159(1):12-21.
24. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58(1):32-45.
25. Sager P.T. Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes. British Journal of Pharmacology 2008, 154(7):1544-1549.
26. Sager P.T., Gintant G., Turner J.R., Pettit S., Stockbridge N. Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium. American Heart Journal 2014, 167(3):292-300.
27. Sällström J., Al-Saffar A., Pehrson R. Pharmacokinetic-pharmacodynamic modeling of QRS-prolongation by flecainide: heart rate-dependent effects during sinus rhythm in conscious telemetered dogs. Journal of Pharmacological and Toxicological Methods 2014, 69(1):24-29.
28. Stett A., Egert U., Guenther E., Hofmann F., Meyer T., Nisch W., Haemmerle H. Biological application of microelectrode arrays in drug discovery and basic research. Analytical and Bioanalytical Chemistry 2003, 377(3):486-495.
29. Takasuna K., Manabe S. Pre-clinical QT risk assessment in pharmaceutical companies - Issues of current QT risk assessment. Biomolecules & Therapeutics 2009, 17(1):1-11.
30. Toyoshima S., Kanno A., Kitayama T., Sekiya K., Nakai K., Haruna M., Mino T., Miyazaki H., Yano K., Yamamoto K. QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. Journal of Pharmacological Sciences 2005, 99(5):459-471.
31. Webster R., Allan G., Anto-Awuakye K., Harrison A., Kidd T., Leishman D., Walker D. Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog. Xenobiotica 2001, 31(8-9):633-650.
32. Yamazaki K., Hihara T., Taniguchi T., Kohmura N., Yoshinaga T., Ito M., Sawada K. A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval. Toxicology In Vitro 2012, 26(2):335-342.